BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27673558)

  • 1. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer.
    Honda K; Srivastava S
    Biomark Med; 2016 Nov; 10(11):1197-1207. PubMed ID: 27673558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification of pancreatic cancer by a blood test for apolipoprotein A2-isoforms.
    Honda K
    Cancer Biomark; 2022; 33(4):503-512. PubMed ID: 35491769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma biomarker for detection of early stage pancreatic cancer and risk factors for pancreatic malignancy using antibodies for apolipoprotein-AII isoforms.
    Honda K; Kobayashi M; Okusaka T; Rinaudo JA; Huang Y; Marsh T; Sanada M; Sasajima Y; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Miura N; Kamita M; Sakamoto T; Shoji H; Jung G; Srivastava S; Yamada T
    Sci Rep; 2015 Nov; 5():15921. PubMed ID: 26549697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA19-9 and apolipoprotein-A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation.
    Honda K; Katzke VA; Hüsing A; Okaya S; Shoji H; Onidani K; Olsen A; Tjønneland A; Overvad K; Weiderpass E; Vineis P; Muller D; Tsilidis K; Palli D; Pala V; Tumino R; Naccarati A; Panico S; Aleksandrova K; Boeing H; Bueno-de-Mesquita HB; Peeters PH; Trichopoulou A; Lagiou P; Khaw KT; Wareham N; Travis RC; Merino S; Duell EJ; Rodríguez-Barranco M; Chirlaque MD; Barricarte A; Rebours V; Boutron-Ruault MC; Romana Mancini F; Brennan P; Scelo G; Manjer J; Sund M; Öhlund D; Canzian F; Kaaks R
    Int J Cancer; 2019 Apr; 144(8):1877-1887. PubMed ID: 30259989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer.
    Kashiro A; Kobayashi M; Oh T; Miyamoto M; Atsumi J; Nagashima K; Takeuchi K; Nara S; Hijioka S; Morizane C; Kikuchi S; Kato S; Kato K; Ochiai H; Obata D; Shizume Y; Konishi H; Nomura Y; Matsuyama K; Xie C; Wong C; Huang Y; Jung G; Srivastava S; Kutsumi H; Honda K
    J Gastroenterol; 2024 Mar; 59(3):263-278. PubMed ID: 38261000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma.
    Audisio RA; Veronesi P; Maisonneuve P; Chiappa A; Andreoni B; Bombardieri E; Geraghty JG
    Surg Oncol; 1996 Apr; 5(2):49-63. PubMed ID: 8853239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in biomarker discoveries for the early detection and risk stratification of pancreatic cancer using omics studies.
    Kobayashi T; Honda K
    Expert Rev Mol Diagn; 2019 Aug; 19(8):651-654. PubMed ID: 31298060
    [No Abstract]   [Full Text] [Related]  

  • 8. Early detection markers in Pancreas Cancer.
    Farrell JJ; van Rijnsoever M; Elsaleh H
    Cancer Biomark; 2005; 1(2-3):157-75. PubMed ID: 17192037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tumour markers of pancreatic cancer (tumour associated antigens)].
    Groblewska M; Mroczko B; Szmitkowski M
    Pol Arch Med Wewn; 2005 Jun; 113(6):585-93. PubMed ID: 16454450
    [No Abstract]   [Full Text] [Related]  

  • 10. A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1994 Mar; 69(3):562-5. PubMed ID: 8123488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum apolipoprotein A2 isoforms in autoimmune pancreatitis.
    Kobayashi T; Sato Y; Nishiumi S; Yagi Y; Sakai A; Shiomi H; Masuda A; Okaya S; Kutsumi H; Yoshida M; Honda K
    Biochem Biophys Res Commun; 2018 Mar; 497(3):903-907. PubMed ID: 29481802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1993 Apr; 67(4):852-5. PubMed ID: 8471445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of diagnostic value of serum Carbohydrate antigen 199 in pancreatic cancer.
    Zhang Y; Jiang L; Song L
    Minerva Med; 2016 Feb; 107(1):62-9. PubMed ID: 26824636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
    Satake K; Takeuchi T
    Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer.
    Kato S; Honda K
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.
    Huang T; Jiang SW; Qin L; Senkowski C; Lyle C; Terry K; Brower S; Chen H; Glasgow W; Wei Y; Li J
    Int J Mol Sci; 2015 Jan; 16(2):2956-70. PubMed ID: 25642754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis.
    Deng T; Yuan Y; Zhang C; Zhang C; Yao W; Wang C; Liu R; Ba Y
    Cell Physiol Biochem; 2016; 39(5):1716-1722. PubMed ID: 27639768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
    Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
    PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.